Perioperative substance P/NK1R pharmacology: from PONV control to a testable cancer neuro-immune hypothesis - Top-Institutions - MDSpire

Perioperative substance P/NK1R pharmacology: from PONV control to a testable cancer neuro-immune hypothesis

  • By

  • Jing Zhao

  • Zhongwei Liu

  • Jun Wang

  • July 16, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Anesthesiology
    • Oncology

  • #2

    Duke University Hospital
    Duke University Hospital

    Durham, North Carolina

    Key Differentiators

    • Anesthesiology
    • Oncology

Original Source(s)

Perioperative substance P/NK1R pharmacology: from PONV control to a testable cancer neuro-immune hypothesis

  • by Jing Zhao, Zhongwei Liu, Jun Wang

  • July 16, 2026

Related Content

Research progress of small molecule targeted drugs for non-small cell lung cancer

Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC

Financial distress among women with advanced or metastatic breast cancer in Germany: secondary analysis of prospective ePROCOM data of a two-center cohort